Emmaus Life Sciences Announces the New England Journal of Medicine has Published the Phase 3 Trial Results of Endari? (L-Glutamine Oral Powder) in Sickle Cell Disease 07.18.2018. Emmaus Life Sciences Announces Availability of Endari? (L-glutamine oral powder) for Sickle Cell Disease in the United States 01.17.2018. The U.S. Food & Drug Administration Approves Endari? (L-glutamine oral powder), the First and Only Treatment for Sickle Cell Disease in Pediatric Patients and First in Nearly 20 Years for Adults 07.07.2017. Emmaus Life Sciences, Inc. Receives Japanese Patent for use of L-glutamine in Treatment of Diverticulosis 12.13.2016.